Silmitasertib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against casein kinase II subunit alpha' and casein kinase II subunit alpha. In addition, it is known to target death-associated protein kinase 3, homeodomain-interacting protein kinase 3, and serine/threonine-protein kinase pim-1.
|Drug Class||Serine/threonine kinase inhibitors|